BD Announces Appointment of Zachary A. Nagle as Vice President, Investor Relations

News provided by

Jul 29, 2010, 11:30 ET

FRANKLIN LAKES, N.J., July 29 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Zachary A. Nagle has joined the Company as Vice President, Investor Relations. In this role, Mr. Nagle will serve as the primary liaison between BD and its investors, analysts and the financial community globally.

Mr. Nagle brings 16 years of experience to his new role, most recently serving as Vice President of Investor Relations at Flowserve Corporation in Dallas, Texas, one of the world's leading providers of fluid motion and control products and services.

"Zac is a seasoned investor relations leader who has a deep understanding of the investment community," said David V. Elkins, Executive Vice President and Chief Financial Officer. "His extensive experience working in investor relations and finance functions within Fortune 500 companies will bring added value and enhance our ability to effectively communicate with BD's investors and shareholders."

Prior to joining Flowserve, Mr. Nagle held a number of key executive positions in general management, finance, marketing, strategy and operations at Fortune 500 companies. These include serving as Senior Vice President of Competitive Planning and Analysis at Computer Associates in New York City. He also held roles as Director of Investor Relations and General Manager of Dell, Inc.'s U.S. Consumer Retail Division, as well director positions in finance and marketing for that division. Mr. Nagle also served as a Senior Finance Manager for Procter & Gamble in Cincinnati, Ohio.

Mr. Nagle earned his MBA in finance and marketing from the University of Michigan. He holds a Bachelor of Arts degree in economics and business from the University of Notre Dame.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.